Clinical Trial Detail

NCT ID NCT03843528
Title Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Johns Hopkins All Children's Hospital
Indications

juvenile myelomonocytic leukemia

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Azacitidine + Vorinostat

Age Groups: adult child

No variant requirements are available.